LINVOSELTAMAb promised in multiple tendencies at risk

(MedPage Today)-Toronto-backposeltamab (Lynozyfic) in patients with multi-alertelauma (HR-SMM), according to data from the first stage of the second stage experience. With an average follow -up of 3.9 months between 19 evaluation susceptibility …